Paulina Scheuren

Faculty Bio
Social Media / Lab or Research Website
Website (or Lab):
Social Media: https://x.com/scheurenpaulina?lang=en
December 19, 2024

Website (or Lab):
Social Media: https://x.com/scheurenpaulina?lang=en
December 19, 2024

Website (or Lab):
December 19, 2024

Wesam is a postdoctoral fellow at Abdelrahman Lab. He earned his BSc in Pharmaceutical Sciences and MSc in Pharmacology from Alexandria University, Egypt. He then completed his PhD in Pharmacology at the University of Alberta, Canada. With a background in molecular pharmacology, he is interested in exploring the molecular and cellular mechanisms underlying neurodegenerative diseases, specifically Alzheimer’s disease, and developing novel therapeutic options for its management. His current project is focusing on identifying the role of G protein-coupled receptors in the pathophysiology of Alzheimer’s disease.
Website: https://www.linkedin.com/in/wesam-bassiouni-farag-a108a0118/
Dementia, G protein-coupled receptors, Aging
ORCID: https://orcid.org/0000-0001-8410-3960
PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=bassiouni+w&sort=date
Google Scholar: https://scholar.google.ca/citations?user=QR8RClUAAAAJ&hl=en&oi=ao
p
December 19, 2024

Michelle has extensive experience working with diverse methodologies using various types of databases, including administrative linked data, survey-based cohort data, and clinical trial data. Her previous research primarily focused on marginalized populations, such as people using drugs and individuals living with HIV. Her doctoral research focused on unregulated drug use and the effectiveness of its treatment. She applies machine learning techniques to uncover underlying drug use patterns and to understand their relationship with drug treatment engagement within a causal inference framework. Michelle holds a PhD in Public Health and an MSc in Statistics from the University of British Columbia.
Website (or Lab):
December 19, 2024

Fiona is a community pharmacist and health services researcher passionate about improving access to and promoting safe use of prescription medications. She obtained her PhD in Epidemiology from McGill University, following her pharmacy degree and a master’s in Population and Public Health from the University of British Columbia. Her doctoral research focused on how physician-related factors influence the use of potentially inappropriate medications and how, after using these medications, the patient’s health outcomes varied depending on the physician they saw. With pharmacists’ scope of practice being expanded rapidly across Canada, her postdoctoral work (under the supervision of Dr. Colin Dormuth) aims to evaluate the impact of these changes on patients’ health, as well as on the health system at large. Her work draws on methods from epidemiology, pharmacoepidemiology, health services research, and policy evaluation. She has substantial experience analyzing large, population-based administrative datasets from across Canada and the United States. She has also worked as a community pharmacist, specializing in care of older adults in assisted living and residential care settings.
Website (or Lab):
Pharmaceutical Care, Primary Care, Pharmacoepidemiology, Health Services and Policy Research
Evidence-based prescribing of medicines
December 19, 2024

Website (or Lab):
ORCID: 0000-0002-9183-8970
Google Scholar: https://scholar.google.com/citations?user=Vif_G0MAAAAJ&hl=el
December 18, 2024

Email: stephan.schwarz@ubc.ca
Dr. Stephan Schwarz obtained his primary medical degree as well as a postgraduate medical research doctorate from the University of Göttingen/Germany. In 1995, he relocated to Vancouver/Canada to pursue a PhD in Pharmacology & Therapeutics at The University of British Columbia (UBC), followed by a residency in anesthesia and completion of the Royal College of Physician and Surgeons of Canada Clinician Investigator Program (CIP).
In 2004, he became member of the anesthesia staff at St. Paul’s Hospital/Providence Health Care, where he subsequently was appointed Anesthesia Research Director, a position he occupied for three terms. Simultaneously, he was appointed as Assistant Professor in the UBC Department of Anesthesiology, Pharmacology & Therapeutics, where he was promoted to Associate Professor with tenure in 2011 and full Professor in 2017.
In 2014, Dr. Schwarz was awarded UBC’s endowed Dr. Jean Templeton Hugill Chairship in Anesthesia. Since then, he has served as Director of the UBC Hugill Anesthesia Research Centre, a collaborative initiative within the UBC Department of Anesthesiology, Pharmacology & Therapeutics under the aegis of the Hugill Chairship. Nationally, Dr. Schwarz has served on the Canadian Anesthesiologists’ Society (CAS) Research Advisory Committee, the CAS Grant Adjudication Subcommittee, and the CAS Ethics Committee.
A passionate lecturer, Dr. Schwarz has been an invited speaker at many national and international conferences and has won numerous research and teaching awards; in 2017, he was awarded a UBC Killam Teaching Prize, UBC’s most prestigious award in recognition of excellence in education.
Using in vitro and in vivo laboratory techniques as well as clinical studies, Dr. Schwarz’ research explores the neuropharmacology of anesthesia and analgesia and aims to build bridges between bench and bedside. A particular area of focus has been local anesthetic pharmacology. His CV lists over 230 published articles and abstracts. His areas of clinical interest are Adult Anesthesia, Regional Anesthesia, and Perioperative Medicine.
Taking advantage of his multidisciplinary training and activities that include clinical anesthesiology; basic neurosciences and pharmacology; evidence-based medicine; experimental design; and data analysis, Dr. Schwarz is a veteran, internationally recognized editorial peer reviewer. He has been presented with “Top Reviewer” awards from Anesthesiology and the Canadian Journal of Anesthesia and has served as a peer reviewer for The Lancet and the New England Journal of Medicine. In 2014, he was appointed to the Editorial Board of the Canadian Journal of Anesthesia and in 2020 was selected as its new Editor-in-Chief, a position which he has occupied since January 1, 2021.
Website (or Lab):
Using in vitro and in vivo laboratory techniques as well as clinical studies, Dr. Schwarz’ research explores the neuropharmacology of anesthesia and analgesia and aims to build bridges between bench and bedside. A particular area of focus has been local anesthetic pharmacology.
General Adult Anesthesia; Regional Anesthesia; Ambulatory Anesthesia; Perioperative Medicine
December 18, 2024

Email: john.kramer@ubc.ca
Website (or Lab):
December 18, 2024

EmEmail: dknight2@providencehealth.bc.ca
Dr. Knight obtained his PhD at the University of Western Australia in 1993 and did post doctoral training at the University of British Columbia. From 1997 to 2001 he was a Senior Research Officer in the Asthma & Allergy Research Institute of the University of Western Australia and was Head of the Experimental Biology division of the Institute from 2002-2004. He was also an Adjunct Senior Lecturer in the Department of Medicine at the University of Western Australia.
Dr. Knight’s research program consists of complementary projects centered on understanding how the respiratory system repairs itself after inflammatory insult and why in susceptible asthmatics, inflammation results in ongoing and abnormal remodeling rather than a self-limited healing process. The particular focus of this program is the epithelial cell and fibroblast in modulating the repair process.
Website (or Lab):
The current objectives of Dr. Knight’s research program are centred on investigating the mechanisms of airway epithelial repair following damage induced by a variety of stimuli focusing on 3 key objectives: (1) Characterize the phenotype of epithelial-resident progenitor cells involved in repair in human airways (2) Determine whether bone marrow derived progenitor cells play a role in epithelial repair, and if so, what is the relative contribution of these cells to tissue resident progenitor cells under normal conditions and in the presence of underlying allergic disease (3) Examine whether airway progenitor cells have potential for both epithelial and mesenchymal differentiation.
Dr. Knight is also actively investigating the role of the IL-6/gp130 in the pathogenesis of pulmonary fibrosis. The specific goal of this project is to identify novel molecular mechanisms for the treatment, diagnosis and prognosis of IPF focusing on our insights that cytokines that signal through gp130 may be critical determinants of disease susceptibility and progression. gp 130 is a shared component in the receptor complexes for the IL-6 family of cytokines that also includes IL-11, Leukemia Inhibitory Factor (LIF) and Oncostatin M (OSM) which are important regulators of both the phenotype and proliferation of fibroblasts in health and in response to injury.
December 18, 2024

Faculty Member in the Department since 2011. Holds his BSc (Pharmacology) and PhD (Physiology) from UBC.
Website (or Lab):
Neurosciences and anesthesiology
Vice Chair, Education
PCTH_V 201 (Course Director)
PCTH_V 404 (Course Director)
PCTH_V 201
PCTH_V 301
PCTH_V 302
PCTH_V 303
PCTH_V 325
PCTH_V 400
PCTH_V 402
PCTH_V 404